An Aging Clock Based on Circulating Amino Acid Levels

Key Takeaways

• AmiAge uses 18 amino acids to predict biological age via Random Forest
• Model trained on >11,000 in‑house and 270,000 public samples
• AmiAge Gap strongly links to frailty, telomere loss, disease risk
• Eight‑amino‑acid version retains accuracy while improving scalability

Pulse Analysis

The surge of biological aging clocks has outpaced rigorous validation, leaving clinicians and researchers uncertain which metrics truly reflect physiological decline. Traditional epigenetic and proteomic clocks require expensive assays and sophisticated data pipelines, limiting their routine use. By focusing on amino acids—molecules already measured in standard metabolic panels—AmiAge bridges the gap between scientific insight and practical application, offering a scalable alternative that can be integrated into existing laboratory workflows.

AmiAge’s strength lies in its massive, heterogeneous training set: more than 11,000 proprietary samples combined with over 270,000 publicly sourced profiles. This breadth captures diverse genetic backgrounds, diets, and health statuses, enabling the Random Forest model to discern subtle age‑related shifts in amino acid concentrations. The resulting AmiAge Gap shows strong concordance with established biomarkers such as telomere length, inflammatory markers, and frailty indices, and it predicts higher incidence of chronic diseases. The distilled eight‑amino‑acid version—featuring alanine, glutamine, glycine, histidine, leucine, phenylalanine, tyrosine, and valine—maintains predictive power while reducing assay costs, making it attractive for large‑scale epidemiological studies and clinical trials.

For the biotech and pharmaceutical sectors, AmiAge could become a valuable endpoint in trials of senolytics, metabolic modulators, and lifestyle interventions. Its ease of measurement enables frequent monitoring, facilitating adaptive trial designs and personalized dosing strategies. Moreover, health‑tech platforms can leverage the clock to offer users actionable insights into their biological age trajectory, driving consumer engagement and preventive care. As the market seeks reliable, affordable aging biomarkers, AmiAge’s amino‑acid foundation positions it as a pragmatic complement to more complex clocks, potentially accelerating the translation of longevity research into real‑world health outcomes.